Recent Announcements

Updated When and In Whom to Initiate Therapy

The introductory statement of When and In Whom to Initiate Therapy has been revised to reiterate that treatment will benefit almost all patients in all stages of chronic infection and that urgent initiation of therapy is needed in patients with certain conditions.

Read More

US FDA Approval of Ledipasvir/Sofosbuvir

The panel is meeting and currently reviewing data to update the Guidance based on the US FDA approval of ledipasvir/sofosbuvir. The updated Guidance will be posted in early December.

Read More

Updated Introductory Statement of When and In Whom to Initiate Therapy

The introductory statement of When and In Whom to Initiate Therapy has been revised to reiterate that treatment will benefit almost all patients in all stages of chronic infection and that urgent initiation of therapy is needed in patients with certain conditions.

Read More

New Section: Management of Acute HCV Infection

The newest section of the AASLD/IDSA/IAS–USA hepatitis C Guidance, Management of Acute HCV Infection, is now available. Click here to access this section.

Read More

Updated Information on Drug Interactions

Updated information on drug interactions between simeprevir and certain immunosuppressant drugs has been added based on the manufacturer's revised product prescribing information. For more information see Unique Patient Populations.

Read More

Updated Statement on Drug-drug Interactions

Simeprevir concentration is increased by approximately 6-fold when coadministered with cyclosporine (in combination with daclatasvir [an investigational drug] and RBV). Coadministration of simeprevir with cyclosporine is not recommended. For more information see Unique Patient Populations.

Read More

New Section: When and In Whom to Initiate HCV Therapy

We are pleased to introduce the newest section of the Guidance, When and in Whom to Initiate HCV Therapy. Successful hepatitis C treatment results in sustained virologic response (SVR), which is tantamount to virologic cure; virologic cure is expected to benefit chronically infected persons.

Read More

Official Press Release - When and In Whom to Initiate HCV Therapy

View Official Press Release: When and In Whom to Initiate HCV Therapy Now Available at www.HCVguidelines.org

Read More

How to Cite and Request Permission to Reprint or Use Content in the Guidance

How to cite the Guidance in papers

The website as a whole.
AASLD-IDSA. Recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org. $$$Insert date accessed here$$$.

A section or specific page on the website.
For example, if citing the HCV Testing and Linkage to Care section:
AASLD-IDSA. HCV testing and linkage to care. Recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org/full-report/hcv-testing-and-linkage-care. $$$Insert date accessed here$$$.

Read More
Top